The current place and indications of 131I-metaiodobenzylguanidine therapy in the era of peptide receptor radionuclide therapy

Basu, Sandip; Abhyankar, Amit; Jatale, Prafful

doi:10.1097/mnm.0000000000000209

Cited by 9 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[123] We endeavored to evaluate the disease status using FDG-PET and to assess its impact on further management. Papaioannou and McHugh[7] in their review concluded that FDG-PET could emerge as a promising modality for revealing childhood neuroblastoma, whereas Shulkin et al .…”

Section: Discussionmentioning

confidence: 99%

“…[123] These functionally and metabolically active amine precursor uptake and decarboxylation cell-derived tumors form a large heterogeneous group of malignancies and demonstrate increased circulating and urinary levels of the secreted hormones and their metabolites. [123] Conventional anatomic imaging modalities (such as ultrasonography, computed tomography [CT], and magnetic resonance imaging [MRI]) are the initial investigational method commonly employed, on early clinicobiochemical suspicion, though they may fail to detect these small tumors with micrometastasis and especially cannot depict their unique functionality. [134]…”

Section: Introductionmentioning

confidence: 99%

“…[123] Conventional anatomic imaging modalities (such as ultrasonography, computed tomography [CT], and magnetic resonance imaging [MRI]) are the initial investigational method commonly employed, on early clinicobiochemical suspicion, though they may fail to detect these small tumors with micrometastasis and especially cannot depict their unique functionality. [134]…”

Section: Introductionmentioning

confidence: 99%

“…[12] The reported sensitivity and specificity of iodine-131 MIBG ( 131 I-MIBG) are quite high (≥90%) for pheochromocytoma and neuroblastoma while that for medullary carcinoma of the thyroid (MCT) are much lower about 30%. [34] The 131 I-MIBG avidity does vary due to some de novo factors or disease course-related causes. [345] In recent times, 18-fluorodeoxyglucose positron emission tomography (FDG-PET) has been investigated for potential roles in these relatively rare groups of tumors in tissue characterization, metastatic potential evaluation, and predicting prognosis.…”

Section: Introductionmentioning

confidence: 99%

“…[34] The 131 I-MIBG avidity does vary due to some de novo factors or disease course-related causes. [345] In recent times, 18-fluorodeoxyglucose positron emission tomography (FDG-PET) has been investigated for potential roles in these relatively rare groups of tumors in tissue characterization, metastatic potential evaluation, and predicting prognosis. [45]…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Comparative evaluation of iodine-131 metaiodobenzylguanidine and 18-fluorodeoxyglucose positron emission tomography in assessing neural crest tumors: Will they play a complementary role?

Kundu

Kand

Basu

2017

South Asian J Cancer

Self Cite

View full text Add to dashboard Cite

Background:18-Fluorodeoxyglucose positron emission tomography (FDG-PET) has established a role in the evaluation of several malignancies. However, its precise clinical role in the neural crest cell tumors continues to evolve.Purpose:The purpose of this study was to compare iodine-131 metaiodobenzylguanidine (131I-MIBG) and FDG-PET of head to head in patients with neural crest tumors both qualitatively and semiquantitatively and to determine their clinical utility in disease status evaluation and further management.Materials and Methods:A total of 32 patients who had undergone 131I-MIBG and FDG-PET prospectively were evaluated and clinicopathologically grouped into three categories: neuroblastoma, pheochromocytoma, and medullary carcinoma thyroid.Results:In 18 patients of neuroblastoma, FDG PET and 131I-MIBG showed patient-specific sensitivity of 84% and 72%, respectively. The mean maximum standardized uptake value (SUVmax) of primary lesions in patients with unfavorable histology was found to be relatively higher than those with favorable histology (5.18 ± 2.38 vs. 3.21 ± 1.69). The mean SUVmaxof two common sites (posterior superior iliac spine [PSIS] and greater trochanter) was higher in patients with involved marrow than those with uninvolved one (2.36 and 2.75 vs. 1.26 and 1.34, respectively). The ratio of SUVmaxof the involved/contralateral normal sites was 2.16 ± 1.9. In equivocal bone marrow results, the uptake pattern with SUV estimation can depict metastatic involvement and help in redirecting the biopsy site. Among seven patients of pheochromocytoma, FDG-PET revealed 100% patient-specific sensitivity. FDG-PET detected more metastatic foci than 131I-MIBG (18 vs. 13 sites). In seven patients of medullary carcinoma thyroid, FDG-PET localized residual, recurrent, or metastatic disease with much higher sensitivity (32 metastatic foci with 72% patient specific sensitivity) than 131I-MIBG, trending along the higher serum calcitonin levels.Conclusions:FDG-PET is not only a good complementary modality in the management of neural crest cell tumors but also it can even be superior, especially in cases of 131I-MIBG nonavid tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Comparative evaluation of iodine-131 metaiodobenzylguanidine and 18-fluorodeoxyglucose positron emission tomography in assessing neural crest tumors: Will they play a complementary role?

Kundu

Kand

Basu

2017

South Asian J Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

Management of Locally Advanced and Metastatic Pheochromocytoma and Paraganglioma

Román-Gonzaléz¹,

Vásquez²,

Hyde

et al. 2016

Management of Adrenal Masses in Children and Adults

View full text Add to dashboard Cite

Treatment for Malignant Pheochromocytomas and Paragangliomas: 5 Years of Progress

et al. 2017

View full text Add to dashboard Cite

The manuscript will describe the clinical predictors of survivorship and their influence on the first TNM staging classification for pheochromocytomas and sympathetic paragangliomas, the treatment of hormonal complications, and the rationale that supports the resection of the primary tumor and metastases in patients with otherwise incurable disease. Therapeutic options for patients with bone metastasis to the spine will be presented. The manuscript will also review chemotherapy and propose a maintenance regimen with dacarbazine for patients initially treated with cyclophosphamide, vincristine, and dacarbazine. Finally, the manuscript will review preliminary results of several phase 2 clinical trials of novel radiopharmaceutical agents and tyrosine kinase inhibitors. MPPGs are very rare neuroendocrine tumors. MPPGs are usually characterized by a large tumor burden, excessive secretion of catecholamines, and decreased overall survival. Recent discoveries have enhanced our knowledge of the pathogenesis and phenotypes of MPPG. This knowledge is leading to a better understanding of the indications and limitations of the currently available localized and systemic therapies as well as the development of phase 2 clinical trials for novel medications.

show abstract

The current place and indications of 131I-metaiodobenzylguanidine therapy in the era of peptide receptor radionuclide therapy

Cited by 9 publications

References 19 publications

Comparative evaluation of iodine-131 metaiodobenzylguanidine and 18-fluorodeoxyglucose positron emission tomography in assessing neural crest tumors: Will they play a complementary role?

Comparative evaluation of iodine-131 metaiodobenzylguanidine and 18-fluorodeoxyglucose positron emission tomography in assessing neural crest tumors: Will they play a complementary role?

Management of Locally Advanced and Metastatic Pheochromocytoma and Paraganglioma

Treatment for Malignant Pheochromocytomas and Paragangliomas: 5 Years of Progress

Contact Info

Product

Resources

About